Your browser doesn't support javascript.
loading
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities.
Narli Özdemir, Zehra; Kiliçaslan, Necati Alp; Yilmaz, Musa; Eskazan, Ahmet Emre.
Affiliation
  • Narli Özdemir Z; Department of Hematology, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey.
  • Kiliçaslan NA; Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Eskazan AE; Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Fatih, Istanbul, Turkey. emre.eskazan@iuc.edu.tr.
Int J Hematol ; 117(1): 3-15, 2023 Jan.
Article in En | MEDLINE | ID: mdl-36064839
Patients diagnosed with chronic myeloid leukemia (CML) in chronic phase can now have a life expectancy comparable to that of the general population thanks to the use of tyrosine kinase inhibitor (TKI) therapies. Although most patients with CML require lifelong TKI therapy, it is possible for some patients to achieve treatment-free remission. These spectacular results have been made possible by the development of superior treatment modalities as well as clinicians' efforts in strictly adhering to clinical guidelines such as the National Comprehensive Cancer Network (NCCN) and European Leukemia Network (ELN). CML treatment recommendations reported in these guidelines are the result of years of selecting and incorporating the most reliable evidence. In this review, we provide a synopsis of the differences and similarities that exist between the NCCN and ELN guidelines.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Protein Kinase Inhibitors Type of study: Guideline Limits: Humans Language: En Journal: Int J Hematol Journal subject: HEMATOLOGIA Year: 2023 Type: Article Affiliation country: Turkey

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Protein Kinase Inhibitors Type of study: Guideline Limits: Humans Language: En Journal: Int J Hematol Journal subject: HEMATOLOGIA Year: 2023 Type: Article Affiliation country: Turkey